Androgen receptor polyQ alleles and COVID-19 severity in men : A replication study
© 2022 The Authors. Andrology published by Wiley Periodicals LLC on behalf of American Society of Andrology and European Academy of Andrology..
BACKGROUND: Ample evidence indicates a sex-related difference in severity of COVID-19, with less favorable outcomes observed in men. Genetic factors have been proposed as candidates to explain this difference. The polyglutamine (polyQ) polymorphism in the androgen receptor gene has been recently described as a genetic biomarker of COVID-19 severity.
OBJECTIVE: To test the association between the androgen receptor polyQ polymorphism and COVID-19 severity in a large cohort of COVID-19 male patients.
MATERIALS AND METHODS: This study included 1136 male patients infected with SARS-CoV-2 as confirmed by positive PCR. Patients were retrospectively and prospectively enrolled from March to November 2020. Patients were classified according to their severity into three categories: oligosymptomatic, hospitalized and severe patients requiring ventilatory support. The number of CAG repeats (polyQ polymorphism) at the androgen receptor was obtained by PCR and patients were classified as either short (<23 repeats) or long (≥23 repeats) allele carriers. The association between polyQ alleles (short or long) and COVID-19 severity was assessed by Chi-squared (Chi2 ) and logistic regression analysis.
RESULTS: The mean number of polyQ CAG repeats was 22 (±3). Patients were classified as oligosymptomatic (15.5%), hospitalized (63.2%), and severe patients (21.3%) requiring substantial respiratory support. PolyQ alleles distribution did not show significant differences between severity classes in our cohort (Chi2 test p > 0.05). Similar results were observed after adjusting by known risk factors such as age, comorbidities, and ethnicity (multivariate logistic regression analysis).
DISCUSSION: Androgen sensitivity may be a critical factor in COVID-19 disease severity. However, we did not find an association between the polyQ polymorphism and the COVID-19 severity. Additional studies are needed to clarify the mechanism underlying the association between androgens and COVID-19 outcome.
CONCLUSIONS: The results obtained in our study do not support the role of this polymorphism as biomarker of COVID-19 severity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Andrology - 11(2023), 1 vom: 15. Jan., Seite 24-31 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
López-Rodríguez, Rosario [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
26700-71-0 |
|---|
| Anmerkungen: |
Date Completed 16.12.2022 Date Revised 15.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/andr.13339 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348889208 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348889208 | ||
| 003 | DE-627 | ||
| 005 | 20231226041331.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/andr.13339 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1162.xml |
| 035 | |a (DE-627)NLM348889208 | ||
| 035 | |a (NLM)36375449 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a López-Rodríguez, Rosario |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Androgen receptor polyQ alleles and COVID-19 severity in men |b A replication study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2022 | ||
| 500 | |a Date Revised 15.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Authors. Andrology published by Wiley Periodicals LLC on behalf of American Society of Andrology and European Academy of Andrology. | ||
| 520 | |a BACKGROUND: Ample evidence indicates a sex-related difference in severity of COVID-19, with less favorable outcomes observed in men. Genetic factors have been proposed as candidates to explain this difference. The polyglutamine (polyQ) polymorphism in the androgen receptor gene has been recently described as a genetic biomarker of COVID-19 severity | ||
| 520 | |a OBJECTIVE: To test the association between the androgen receptor polyQ polymorphism and COVID-19 severity in a large cohort of COVID-19 male patients | ||
| 520 | |a MATERIALS AND METHODS: This study included 1136 male patients infected with SARS-CoV-2 as confirmed by positive PCR. Patients were retrospectively and prospectively enrolled from March to November 2020. Patients were classified according to their severity into three categories: oligosymptomatic, hospitalized and severe patients requiring ventilatory support. The number of CAG repeats (polyQ polymorphism) at the androgen receptor was obtained by PCR and patients were classified as either short (<23 repeats) or long (≥23 repeats) allele carriers. The association between polyQ alleles (short or long) and COVID-19 severity was assessed by Chi-squared (Chi2 ) and logistic regression analysis | ||
| 520 | |a RESULTS: The mean number of polyQ CAG repeats was 22 (±3). Patients were classified as oligosymptomatic (15.5%), hospitalized (63.2%), and severe patients (21.3%) requiring substantial respiratory support. PolyQ alleles distribution did not show significant differences between severity classes in our cohort (Chi2 test p > 0.05). Similar results were observed after adjusting by known risk factors such as age, comorbidities, and ethnicity (multivariate logistic regression analysis) | ||
| 520 | |a DISCUSSION: Androgen sensitivity may be a critical factor in COVID-19 disease severity. However, we did not find an association between the polyQ polymorphism and the COVID-19 severity. Additional studies are needed to clarify the mechanism underlying the association between androgens and COVID-19 outcome | ||
| 520 | |a CONCLUSIONS: The results obtained in our study do not support the role of this polymorphism as biomarker of COVID-19 severity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a androgen receptor | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a polyQ polymorphism | |
| 650 | 4 | |a sex-related differences | |
| 650 | 7 | |a Receptors, Androgen |2 NLM | |
| 650 | 7 | |a polyglutamine |2 NLM | |
| 650 | 7 | |a 26700-71-0 |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Ruiz-Hornillos, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Cortón, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Almoguera, Berta |e verfasserin |4 aut | |
| 700 | 1 | |a Minguez, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Tomás, María Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Barreda-Sánchez, María |e verfasserin |4 aut | |
| 700 | 1 | |a Mancebo, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Ondo, Lorena |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Ramas, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Caballero, Lidia |e verfasserin |4 aut | |
| 700 | 1 | |a Taracido-Fernández, Juan Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Herrero-González, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Mahillo, Ignacio |e verfasserin |4 aut | |
| 700 | 0 | |a STOP_Coronavirus Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Paz-Artal, Estela |e verfasserin |4 aut | |
| 700 | 1 | |a Guillén-Navarro, Encarna |e verfasserin |4 aut | |
| 700 | 1 | |a Ayuso, Carmen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Andrology |d 2013 |g 11(2023), 1 vom: 15. Jan., Seite 24-31 |w (DE-627)NLM223616559 |x 2047-2927 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:1 |g day:15 |g month:01 |g pages:24-31 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/andr.13339 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 1 |b 15 |c 01 |h 24-31 | ||